R2WA Stock Overview
Manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 6/6 |
Beximco Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳0.40 |
| 52 Week High | ৳0.50 |
| 52 Week Low | ৳0.23 |
| Beta | 0.62 |
| 11 Month Change | -0.50% |
| 3 Month Change | 27.74% |
| 1 Year Change | n/a |
| 33 Year Change | -66.15% |
| 5 Year Change | -11.82% |
| Change since IPO | -20.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| R2WA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.0% | -1.3% |
| 1Y | n/a | -22.0% | 7.4% |
Return vs Industry: Insufficient data to determine how R2WA performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how R2WA performed against the German Market.
Price Volatility
| R2WA volatility | |
|---|---|
| R2WA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: R2WA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine R2WA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 5,700 | Iqbal Ahmed | www.beximcopharma.com |
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids.
Beximco Pharmaceuticals Limited Fundamentals Summary
| R2WA fundamental statistics | |
|---|---|
| Market cap | €291.52m |
| Earnings (TTM) | €47.24m |
| Revenue (TTM) | €356.45m |
6.2x
P/E Ratio0.8x
P/S RatioIs R2WA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R2WA income statement (TTM) | |
|---|---|
| Revenue | ৳44.95b |
| Cost of Revenue | ৳25.04b |
| Gross Profit | ৳19.90b |
| Other Expenses | ৳13.95b |
| Earnings | ৳5.96b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 13.35 |
| Gross Margin | 44.28% |
| Net Profit Margin | 13.25% |
| Debt/Equity Ratio | 9.2% |
How did R2WA perform over the long term?
See historical performance and comparison